Clinical trials: Renal Dysfunction
Renal Insufficiency, Healthy
A Study of LY3819469 in Participants With Impaired and Normal Renal Function
The main purpose of this study is to assess the amount of study drug (LY3819469) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared…
- Trial name
- NCT05841277
- Testing
- LY3819469
- Where
- 4 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Chronic Renal Diseases
Intradialytic Physiotherapy in Patients With Chronic Kidney Disease
The objective is to evaluate in adult patients with chronic kidney disease the effect of neuromuscular electrical stimulation (NMES) in the upper limbs associated with a cycle ergometer in the lower limbs, during hemodialysis, on…
- Trial name
- NCT05374863
- Testing
- Neuromuscular electrical stimulation (NMES) - Active, Aerobic exercise with cycle ergometer
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Marcela Cangussu Barbalho
Respiratory Failure, Respiratory Arrest
Postoperative Respiratory Abnormalities
The study aims to determine how historical cases of respiratory abnormalities are documented by clinicians in the electronic health records (EHR) of Memorial Hermann Healthcare System (MHHS) inpatient facilities.
- Conditions
- Respiratory Failure, Respiratory Arrest, Respiratory Distress Syndrome, Acute Respiratory Failure
- Trial name
- AI-ARF (NCT04079829)
- Testing
- Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
- Where
- United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Efficacy Care R&D Ltd
Schizophrenia, Renal Impairment
A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function
The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of 3 mg extended release paliperidone (ER OROSÃ' paliperidone) in patients with varying degrees of renal impairment (mild, moderate, and severe)…
- Trial name
- NCT00791401
- Testing
- ER OROS Paliperidone
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Clinical Pharmacology
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
BAY 63-2521 is intended to be used for a disease that affects the blood flow through the lungs. Renal impairment is a common condition in patients with this disease.
- Trial name
- NCT04364464
- Testing
- Riociguat (Adempas, BAY 63-2521)
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Kidney Diseases
Systemic Redesign and Demonstration for Early Detection, Evaluation and Management of Chronic Kidney Disease in Shanghai
Based on clinical evidence based medicine and organizational management model, investigators redesign the prevention and treatment of chronic kidney disease of public health system in Shanghai China.
- Trial name
- SCREENING (NCT03084172)
- Where
- 34 sites in China
- Volunteers
- 2,000,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Chronic Renal Disease, Chronic Renal Insufficiency
2D-speckle Tracking in Pediatric Renal Chronic Disease
The SPECKLE- KIDNEY-PED is a multicentre observational controlled trial aiming to evaluate the 2D-Speckle tracking in a population of 85 patients aged from 6 to 17 years old with a chronic renal disease and to compare the results…
- Conditions
- Chronic Renal Disease, Chronic Renal Insufficiency, Congenital Heart Disease
- Trial name
- SPECKLEKIDNEY (NCT04897672)
- Testing
- Observational study
- Where
- France
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
This is an open-label study that will measure blood levels of different parts of a drug called GKS189075. People participating in this study will receive a single dose of 250mg GSK189075 by mouth.
- Conditions
- Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency
- Trial name
- NCT00501462
- Testing
- GSK189075
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Renal Insufficiency
Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly
Open pharmacokinetic study with 5 parallel groups and two treatment phases (bemiparin 3,500 IU multiple dose and bemiparin 115 IU/kg single dose).
- Trial name
- NCT00413088
- Testing
- bemiparin
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
COVID-19, Acute Kidney Injury
Kidney Disease After COVID-19
To understand the long-term epidemiology, develop effective risk-prediction and stratification tools, and understand the pathobiology of kidney disease in COVID-19 survivors.
- Conditions
- COVID-19, Acute Kidney Injury, Chronic Kidney Injury
- Trial name
- NCT05328986
- Where
- 5 sites in United States
- Volunteers
- 1,753 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Bacterial Infections
PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment
A Phase 1, open-label, single-dose study to determine the safety and pharmacokinetics of ORAvance (ceftibuten/xeruborbactam oral prodrug [QPX7831]) in participants with renal impairment
- Trial name
- NCT06157242
- Testing
- Xeruborbactam Oral Prodrug, Ceftibuten
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Chronic Kidney Disease Requiring Chronic Dialysis
Activation of the Contact System and the Immune System in Patients With Chronic Kidney Disease.
Patients with end-stage renal disease undergoing hemodialysis (HD) are burdened with extremely high mortality rates (15% per year) and during the early stage (≤120days) the mortality rate is even higher (27% per year).
- Trial name
- AKIM-CKD (NCT05266092)
- Testing
- Observational study
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Solid Tumours
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in subjects with renal impairment and healthy subjects
- Trial name
- NCT02063204
- Testing
- selumetinib
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease
Chronic Kidney Disease at Northeast Taiwan: Biomarker and Multidisciplinary Care
CKD is a global endemic disease with increased comorbidities and mortality. The prevalence and the incidence of the end-stage renal disease (ESRD) are extremely high in Taiwan.
- Trial name
- NCT04300387
- Testing
- multidisciplinary care
- Where
- Taiwan
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
End Stage Renal Disease
Explore Transplant @Home Within Kaiser Permanente Southern California
Today, there are 25 million Americans with chronic kidney disease (CKD) and 660,000 patients in full kidney failure, the final CKD stage, known as end stage renal disease (ESRD).
- Trial name
- NCT03389932
- Testing
- Patient-Guided
- Where
- United States
- Volunteers
- 977 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Congestive Heart Failure
Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function
This is a randomized, double-blind, placebo-controlled, multi-center, sequential cohort study in subjects with congestive heart failure (CHF) and impaired renal function who are on stable furosemide treatment (³ 40 mg daily).
- Trial name
- NCT00568009
- Testing
- SLV320
- Where
- 72 sites in United States, Argentina and 8 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Renal Failure Chronic, Surgery
Laparoscopic Donor Nephrectomy Score, a New Scoring System for Preoperative Prediction of Difficulty of Laparoscopic Donor Nephrectomy
The goal of this multicenter observational study is to develope and validate a new scoring system for preoperative prediction of difficulty of Laparoscopic Donor Nephrectomy. Healthy living kidney donors will be enrolled.
- Trial name
- LAPDOCTOR (NCT05769686)
- Where
- Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Jacopo Romagnoli
End-Stage Renal Disease
Feasibility Study of Arterial Stiffness in Hemodialysis Patients
People with kidney failure have a higher chance of getting disease in the blood vessels and this result in a decreased elasticity of the arteries of their body which make them very stiff or hard.
- Trial name
- NCT02196610
- Testing
- Applanation tonometry
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Pruritus, Kidney Failure, Chronic
Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis
Uremic pruritus is a clinically significant symptom which imposes heavy impact on the quality of life of patients with chronic kidney disease undergoing hemodialysis.
- Trial name
- NCT02432508
- Testing
- Laser acupuncture (Olympic)
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- China Medical University Hospital
Renal Insufficiency
A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function
This is a Phase 1 study to evaluate the pharmacokinetics (PK), safety and tolerability of epetraborole tablets in adult subjects with normal renal function, subjects with various degrees of renal impairment, and subjects with…
- Trial name
- NCT05283746
- Testing
- Epetraborole
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AN2 Therapeutics, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.